Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evogene Ltd.EVGN · Entity 8065 | Chief Development Officer | June 04, 2026 | August 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evogene Ltd.
Report date June 04, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,129 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Purchase · Acquired 1,129 · Balance 1,129 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.31 · Expires 2034-11-20 | Direct | 40,000 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 40,000 F1: The options reported in this row vest over a period of four years, with 25% vesting upon the first anniversary of the November 20, 2024 grant date, and the remainder vesting on an equal quarterly basis (6.25% per quarter) over the following twelve quarters, such that all options will be fully vested on the four-year anniversary of the November 20, 2024 grant date. F2: There were no transactions in the securities reported in this row, and the Reporting Person's holdings in these securities is being provided for informational purposes only. |
Filing footnotes · ownership attribution and instrument terms
F1: The options reported in this row vest over a period of four years, with 25% vesting upon the first anniversary of the November 20, 2024 grant date, and the remainder vesting on an equal quarterly basis (6.25% per quarter) over the following twelve quarters, such that all options will be fully vested on the four-year anniversary of the November 20, 2024 grant date.
F2: There were no transactions in the securities reported in this row, and the Reporting Person's holdings in these securities is being provided for informational purposes only.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Aug 26, 2026 20:00 UTC | Evogene Ltd. EVGN · Entity 8065 | PurchaseOrdinary Shares | 1,129 | $0.60 | $677.40 |
DisclosureSEC source: 0001178913-26-004259 · ownership.xml · nonDerivative · entry 1 Tarcic Gabi · CIK 0002085020 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,129 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.